TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 98.09% | -52.33% | -5.79% | -33.37% | -73.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.28% | -59.22% | -0.18% | -32.71% | -25.44% |
| Operating Income | -24.28% | 59.22% | 0.18% | 32.71% | 25.44% |
| Income Before Tax | -44.73% | 56.20% | -19.56% | 30.93% | 20.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.73% | 56.20% | -19.56% | 30.93% | 20.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.73% | 56.20% | -19.56% | 30.93% | 20.39% |
| EBIT | -24.28% | 59.22% | 0.18% | 32.71% | 25.44% |
| EBITDA | -24.99% | 59.28% | 0.20% | 32.96% | 25.61% |
| EPS Basic | 95.99% | -- | -- | -- | -- |
| Normalized Basic EPS | 95.99% | -- | -- | -- | -- |
| EPS Diluted | 95.99% | -- | -- | -- | -- |
| Normalized Diluted EPS | 95.99% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 3,509.47% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 3,509.47% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |